News

The FDA has accepted and filed for review the Cell Therapeutics’ (CTI) New Drug Application (NDA) for pixantrone as treatment for relapsed or refractory aggressive non-Hodgkin’s lymphoma (NHL).

AspenBio has received a request from the FDA for additional information related to its Premarket Notification 510(k) application for AppyScore test. The application was filed in late June

IntelGenx has reported that the New Drug Application (NDA) filing for the antidepressant – CPI-300 has been accepted by the FDA for standard review. In connection with the

Palio, an inVentiv Health company, has sealed a partnership agreement with Zemoga. The deal is aimed at tackling the changing nature of digital media in the healthcare arena.

Our government is committed to building a competitive advantage for the Canadian private sector and supports these leading-edge technology solutions, said Greg Rickford, Member of Parliament for Kenora.

MultiCell Technologies has been granted US patent: 7566567 by the US Patent and Trademark Office, covering its Fa2N-4 and Ea1C-35 immortalized human hepatocyte cell lines. Reportedly, Fa2N-4 and

Wake Pharma (Wake) has received American Podiatric Medical Association (APMA) seal of approval for its product – Wound-Be-Gone, based on a new oxygen free radical binding technology. Wound-Be-Gone

Anika Therapeutics (Anika) has received approval from Health Canada for Monovisc, its single injection viscosupplement, for the treatment of osteoarthritis of the knee. Anika expects to launch Monovisc

NextPharma has engaged the services of Ron Collins, to represent its business development affairs in the Eastern part of the US and Canada. The move is in response